The discovery of a new treatment for skin cancer , which helps patients with skin cancer, and which reduces the risk of recurrence of the disease again.
And it has been proven that this drug increases the chances of surviving from stage 3 skin cancer. And the Cancer Charity says that providing treatment with the NHS is a great step for cancer patients.
Melanoma is the most aggressive type of skin cancer, affecting around 15,400 new people each year in the UK alone.
And scientists found a genetic mutation called BRAF in almost half of the cases, and about 500 people of these people are in the third stage of the disease. This means that the cancer cells have spread to the skin and lymph vessels near the tumor, but have not yet spread to distant parts of the body.
The new drug, which has been approved by the National Institute for Health and Care Excellence in Britain, provides treatment for patients with skin cancer. This drug consists of a mixture of “diprafenib” and “trametinib”, which can be taken at home in a dose of 5 tablets per day.
This comes after a clinical trial of more than 800 patients found that the risk of recurrence became lower in patients taking the treatment.
After 3 years of surgery, 58% of this group survived without any relapses, compared to 39% of the placebo group.
It has also been found that treatment increases the length of time patients can live by reducing the number of people who contract the disease. However, there were side effects, including fatigue and nausea, that affected 1/3 of the patients taking the treatment.
Jill Knutl, from the British charity Melanoma, said: “We continue to discover more people with skin cancer in the UK, particularly among young adults. This treatment may offer great hope to skin cancer patients, especially those who have had surgery before.”
Skin cancer or melanoma is responsible for a higher proportion of deaths than all other skin cancers, with about 2,400 patients dying in the UK each year.
Mirella Marlowe, director of the Center for Health Assessment, says that before the advent of this treatment, there were no other treatments for people suffering from melanoma in the third stage, or to reduce the risk of recurrence of the disease again. Therefore, this treatment represents a major development in the treatment and disposal of melanoma.
As Professor Ruth Plummer, Professor of Clinical Cancer Medicine at Newcastle University, confirms: “The treatment has the potential to improve the health and
About the Author
